Isabelle Rivière, PhD Appointed Associate Dean and Executive Director of Strategic Development in Precision Therapeutics

Dear Colleagues,

I am delighted to share that Isabelle Rivière, PhD, has joined us in the newly created role of associate dean and executive director of strategic development in precision therapeutics at the Vagelos College of Physicians and Surgeons.

Dr. Rivière will lead the development of strategic collaboration to accelerate the discovery and translation of precision therapeutics at Columbia University. Working across schools and disciplines, including business, health care delivery, policy, and therapeutic development, Dr. Rivière will build institutional frameworks to advance emerging technologies, including cell and gene therapies. She will collaborate with the VP&S research leadership team, Columbia’s clinical trials office and GMP operations, Columbia Technology Ventures, the Columbia Institute for Cell Engineering and Therapy, and colleagues across Engineering, Public Health, Business, and Law, to design sustainable, accessible models that enable innovation and impact in precision medicine.

Dr. Rivière joined Columbia from Takeda, where she served as vice president of cell therapy sciences, focusing on the development of innate immune cell therapies. Prior to Takeda, Dr. Rivière spent nearly 25 years at Memorial Sloan Kettering Cancer Center as faculty and director of the Cell Therapy and Cell Engineering Laboratory, where her lab pioneered IND enabling studies and manufacturing strategies for engineered cell therapies, specifically harnessing T lymphocytes, stem cells, and dopaminergic neurons to treat cancer, genetic disorders, and Parkinson’s disease, respectively. Under her supervision, more than 500 patient drug products were successfully manufactured and infused across multiple phase I/II clinical trials. Her work helped bridge the gap between basic research and clinical application, particularly in the treatment of hematological malignancies and monogenic blood disorders, and enabled FDA Breakthrough and Orphan drug designation for the treatment of acute lymphoblastic leukemia with CD19-CAR T cells in 2014.

Dr. Rivière is a scientific co-founder of Juno Therapeutics, later acquired by BMS, and currently serves as vice president of the American Society of Gene & Cell Therapy. She earned a PhD from the University of Paris, conducted postdoctoral work at the Whitehead Institute at MIT and New York University, and recently completed the Global Health Care Leadership Program at Harvard Medical School.

Dr. Rivière’s experience leading cell therapy manufacturing; chemistry, manufacturing, and controls strategy; translational development; and national and international collaborations will be invaluable as Columbia develops a world-class precision therapeutics platform that is scientifically rigorous, operationally effective, economically sustainable, and focused on improving patient access and outcomes.

Please join me in welcoming Dr. Rivière to Columbia and congratulating her on her new role.

Sincerely,

Stavros Lomvardas, PhD
Interim Vice Dean for Basic Science Research, Vagelos College of Physicians and Surgeons 
Chair, Department of Biochemistry and Molecular Biophysics

Back to top